{"id":462565,"date":"2024-08-08T00:00:00","date_gmt":"2024-08-08T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acrecg0023-2024-biopharma-multiple-sclerosis-access-and-reimbursement-us-2024\/"},"modified":"2026-05-06T11:12:48","modified_gmt":"2026-05-06T11:12:48","slug":"acrecg0023-2024-biopharma-multiple-sclerosis-access-and-reimbursement-us-2024","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acrecg0023-2024-biopharma-multiple-sclerosis-access-and-reimbursement-us-2024\/","title":{"rendered":"Multiple Sclerosis | Access and Reimbursement | US | 2024"},"content":{"rendered":"<p>The multiple sclerosis (MS) therapy market continues to evolve, with each new food and drug administration approved disease-modifying therapy (DMT) further expanding treatment choices. The newest entrants (e.g., Ponvory, Briumvi, Tyruko) and nearest-to-launch emerging therapy (e.g., Glatiramer acetate Depot) have entered \/ will enter established drug classes, while novel Bruton\u2019s tyrosine kinase (BTK) inhibitors will establish a new but potentially crowded class; in each case, demonstrating meaningful differentiation for payers and prescribers will be critical. Meanwhile, the debut of oral generics has introduced a new variable in formulary placement and physician choice, especially in the relapsing MS space. For developers bringing innovative or next-generation DMTs to market, understanding the current and future influence of clinical and economic metrics will be key.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>What is the coverage status of key brands on commercial plans?<\/li>\n<li>How do DMT cost and payer restrictions influence clinical decision-making in MS today?<\/li>\n<li>How receptive are surveyed neurologists and payers to key novel and next-in-class agents?<\/li>\n<li>How is generics and biosimilar competition affecting coverage and prescribing in the MS market?<\/li>\n<li>What coverage and uptake are expected for future BTK inhibitors (e.g., Sanofi\u2019s Tolebrutinib, Roche\u2019s Fenebrutinib, and Novartis\u2019s Remibrutinib)? What clinical and nonclinical differentiators would drive preferential use and coverage terms?<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p>U.S. Access &#038; Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment. Each report includes up-to-date analyses of drug coverage and restriction policies as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies.<\/p>\n<p><strong>Markets covered:<\/strong><strong> <\/strong> United States.<\/p>\n<p><strong>Primary research:<\/strong><\/p>\n<ul>\n<li>Survey of 100 U.S. neurologists.<\/li>\n<li>Survey of 32 U.S. managed care organization (MCO) pharmacy and medical directors (PDs\/MDs).<\/li>\n<\/ul>\n<p><strong>Key companies: <\/strong>Bayer, Biogen, Bristol Myers Squibb, EMD Serono, Immunic Therapeutics, Merck, Novartis, Roche \/ Genentech, Sandoz, Sanofi, TG Therapeutics, Vanda, Viatris \/ Mapi Pharma.<\/p>\n<p><strong>Key drugs: <\/strong>Aubagio \/ teriflunomide, Briumvi, Bafiertam, Copaxone \/ glatiramer acetate, Gilenya \/ fingolimod, interferons, Kesimpta, Lemtrada, Mavenclad, Mayzent, Ocrevus, Ponvory, Tecfidera \/ dimethyl fumarate, Tysabri, Tyruko, Vumerity, Zeposia, BTK inhibitors, Frexalimab,\u00a0GA Depot, IMU-838.<\/p>\n<p><strong>Content highlights:<\/strong><\/p>\n<ul>\n<li>Reimbursement and contracting.<\/li>\n<li>Access and prescribing.<\/li>\n<li>Opportunities and challenges for emerging therapies.<\/li>\n<li>Disease-specific special topics.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-462565","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-multiple-sclerosis","biopharma-geography-us","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/462565","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/462565\/revisions"}],"predecessor-version":[{"id":575925,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/462565\/revisions\/575925"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=462565"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}